Evidence map›Paper›PMID 29770217›Full record

ArticleSAGE open medicine2018

Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database.

Misa Naganuma, Yumi Motooka, Sayaka Sasaoka, Haruna Hatahira, Shiori Hasegawa, Akiho Fukuda, Satoshi Nakao, Kazuyo Shimada, Koseki Hirade, Takayuki Mori and 3 more

Open access · goldAbstract read
In one paragraph

Article in SAGE open medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Contemporary management of metastatic urothelial carcinoma.Investigative and clinical urology · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Misa NaganumaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Yumi MotookaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Sayaka SasaokaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Haruna HatahiraLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Shiori HasegawaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Akiho FukudaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Satoshi NakaoLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Kazuyo ShimadaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Koseki HiradeDepartment of Pharmacy, Kizawa Memorial Hospital, Gifu, Japan.
Takayuki MoriDepartment of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
Tomoaki YoshimuraDepartment of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
Takeshi KatoDepartment of Pharmacy, Kizawa Memorial Hospital, Gifu, Japan.
Mitsuhiro NakamuraLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.ORCID https://orcid.org/0000-0002-5062-5522
Gifu Pharmaceutical University · JPAizawa Hospital · JPOgaki Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPlatinum compounds cause several adverse events, such as nephrotoxicity, gastrointestinal toxicity, myelosuppression, ototoxicity, and neurotoxicity. We evaluated the incidence of renal impairment as adverse events are related to the administration of platinum compounds using the Japanese Adverse Drug Event Report database.

methodsWe analyzed adverse events associated with the use of platinum compounds reported from April 2004 to November 2016. The reporting odds ratio at 95% confidence interval was used to detect the signal for each renal impairment incidence. We evaluated the time-to-onset profile of renal impairment and assessed the hazard type using Weibull shape parameter and used the applied association rule mining technique to discover undetected relationships such as possible risk factor.

resultsIn total, 430,587 reports in the Japanese Adverse Drug Event Report database were analyzed. The reporting odds ratios (95% confidence interval) for renal impairment resulting from the use of cisplatin, oxaliplatin, carboplatin, and nedaplatin were 2.7 (2.5-3.0), 0.6 (0.5-0.7), 0.8 (0.7-1.0), and 1.3 (0.8-2.1), respectively. The lower limit of the reporting odds ratio (95% confidence interval) for cisplatin was >1. The median (lower-upper quartile) onset time of renal impairment following the use of platinum-based compounds was 6.0-8.0 days. The Weibull shape parameter β and 95% confidence interval upper limit of oxaliplatin were <1. In the association rule mining, the score of

conclusionOur findings suggest a potential risk of renal impairment during cisplatin use in real-world setting. The present findings demonstrate that the incidence of renal impairment following cisplatin use should be closely monitored when patients are hypertensive or diabetic, or when they are co-administered furosemide, loxoprofen, or pemetrexed. In addition, healthcare professionals should closely assess a patient's background prior to treatment.

Indexed as

adverse eventPlatinum compoundrenal impairmentthe Japanese Adverse Drug Event Report database

Identifiers

PMID29770217
PMCPMC5946636
OpenAlexW2799794197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.